Retatrutide 60mg - 10 Vials (KIT)

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Retatrutide (also known as Reta or LY3437943) is an experimental peptide medication being developed by Eli Lilly, primarily for weight loss, obesity and metabolic health.

It has attracted significant attention because it targets three different hormone receptors, rather than one or two like existing weight-loss medications.

Retatrutide is known as a triple agonist because it activates:

•GLP-1: Helps reduce appetite, slow stomach emptying and regulate blood sugar.

•GIP: Helps regulate insulin release and glucose metabolism.

•Glucagon: May increase energy expenditure and influence how the body uses stored energy.

Potential benefits being researched:

Significant weight reduction.

Reduced appetite and food cravings.

Improved blood sugar regulation.

Improved metabolic health.

Reduced body fat.

Potential improvements in obesity-related conditions.

Reported side effects in clinical trials include:

Nausea

Vomiting

Diarrhoea

Constipation

Reduced appetite

Increased heart rate

Long-term safety is still being investigated.

Retatrutide is not approved by Australia's TGA. It remains an investigational medication.